General Drug Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
as on 24-07-2024
- Paid Up Capital ₹ 2.50 M
as on 24-07-2024
- Company Age 16 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 12.17 Cr
as on 24-07-2024
- Satisfied Charges ₹ 7.50 M
as on 24-07-2024
- Revenue 1.62%
(FY 2023)
- Profit -65.38%
(FY 2023)
- Ebitda -32.94%
(FY 2023)
- Net Worth 0.69%
(FY 2023)
- Total Assets 22.70%
(FY 2023)
About General Drug
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 2.50 M.
The company currently has active open charges totaling ₹12.17 Cr. The company has closed loans amounting to ₹7.50 M, as per Ministry of Corporate Affairs (MCA) records.
Mukesh Doshi, Hitesh Mukeshkumar, and Yogesh Doshi serve as directors at the Company.
- CIN/LLPIN
U24232MH2008PTC181102
- Company No.
181102
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Apr 2008
- Date of AGM
28 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at General Drug?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mukesh Doshi  | Director | 11-Oct-2009 | Current |
| Hitesh Mukeshkumar | Director | 11-Oct-2009 | Current |
| Yogesh Doshi | Director | 11-Oct-2009 | Current |
Financial Performance of General Drug.
General Drug Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 1.62% increase. The company also saw a substantial fall in profitability, with a 65.38% decrease in profit. The company's net worth moved up by a moderate rise of 0.69%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of General Drug?
In 2023, General Drug had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
N Chimanlal And Co Private LimitedActive 19 years 1 monthMukesh Doshi, Hitesh Mukeshkumar and 1 more are mutual person
- Doshi Medicare Private LimitedActive 18 years 10 months
Mukesh Doshi, Hitesh Mukeshkumar and 1 more are mutual person
- Doshi Mediventures Private LimitedActive 18 years 10 months
Mukesh Doshi, Hitesh Mukeshkumar and 1 more are mutual person
Charges (Loans)
₹121.71 M
₹7.50 M
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 6.75 Cr
- Kotak Mahindra Bank Limited : 5.43 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 20 Dec 2019 | Hdfc Bank Limited | ₹6.75 Cr | Open |
| 27 Nov 2010 | Kotak Mahindra Bank Limited | ₹5.43 Cr | Open |
| 20 May 2010 | Kotak Mahindra Bank Limited | ₹7.50 M | Satisfied |
How Many Employees Work at General Drug?
General Drug has a workforce of 22 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of General Drug, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped General Drug's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
